Comparison of the Soluble Basal Insulin Analog Insulin Detemir With NPH Insulin: A randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy

摘要: OBJECTIVE — Insulin detemir (NN304) is a soluble basal insulin analog developed to cover requirements. This trial aimed compare the blood glucose—lowering effect of with that NPH (NPH) and evaluate two treatments regard intrasubject variation fasting glucose, incidence hypoglycemia, dose requirements, safety. RESEARCH DESIGN AND METHODS multicenter open randomized crossover in 59 type 1 diabetic subjects comprised 2-week run-in period on basal-bolus regimen once daily, followed by 6-week periods optimized therapy either once-daily or insulin. RESULTS The area under curve, time interval 23:00-8:00, derived from 24-h serum glucose profiles, was not statistically significantly different for treatment (insulin detemir:NPH ratio 89.2:83.5, P = 0.59). during last 4 days lower compared ( < 0.001). Mean requirements were 2.35 times higher (95% CI 2.22-2.48) NPH. During week treatment, fewer experienced hypoglycemic episodes (60%) (77%) 0.049). CONCLUSIONS as effective maintaining glycemic control when administered at molar dose. results indicate may provide more predictable reduced risk hypoglycemia